Attentional Mechanisms of Cognitive Compensation in Subjective Cognitive Decline
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 80
- 试验地点
- 2
- 主要终点
- Peak P1 amplitude for Orienting
研究概览
简要总结
This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic function. The investigators anticipate that SCD will be associated with greater compensatory attention network activity and that disrupting this compensatory process through anticholinergic challenge will result in a greater negative effect on attentional performance (Attention Network Test, ANT) and attention network functioning (EEG) in older adults with greater subjective cognitive concern.
详细描述
Overview: Cognitively normal older adults with and without subjective cognitive decline (SCD) (n = 80) will complete two study visits that will be double blinded and randomized for anticholinergic challenge (mecamylamine or placebo). Drug challenge visits will include cognitive testing and an electroencephalography (EEG) session.
AIM 1: Test for anticholinergic effects on attentional network function by cognitive concern severity. Under anticholinergic challenge, compared to placebo, greater subjective cognitive concerns will be associated with…:
Hyp. 1a: greater reduction in orienting attention network activity (ERP amplitude for early attention orienting).
Hyp. 1b: greater negative change in orienting attention performance.
Screening Procedures:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Montreal Cognitive Assessment (MoCA) > 25 AND Global Deterioration Scale (GDS) rating < 3
- •Non-smokers
排除标准
- •medical contraindications to the drug challenge
- •primary neurological disorder (such as stroke, epilepsy, etc.)
研究组 & 干预措施
Placebo Challenge
All participants will receive oral placebo for 1 day
干预措施: Placebo Comparator Challenge (Other)
Anticholinergic Challenge
All participants will receive oral mecamylamine for 1 day
干预措施: Mecamylamine Challenge (Drug)
结局指标
主要结局
Peak P1 amplitude for Orienting
时间窗: After administration of second drug challenge, approximately 72 hours
Peak P1 amplitude in parietal regions for Orienting trials of the Attention Network Test (ANT) dyrung anticholinergic challenge
次要结局
未报告次要终点
研究者
Kimberly Albert
Research Assitant Professor, Psychiatry
Vanderbilt University Medical Center